Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant melanoma prognostic factors 7: elective lymph node dissection.

C L Day, R A Lew

    The Journal of Dermatologic Surgery and Oncology
    |March 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The RING Domain of RING Finger 12 Efficiently Builds Degradative Ubiquitin Chains.

    Journal of molecular biology·2020
    Same author

    Trends in usage of the terms keratinocyte carcinoma and nonmelanoma skin cancer in the medical literature.

    The British journal of dermatology·2019
    Same author

    Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.

    The Journal of infectious diseases·2013
    Same author

    Observations on an outbreak of trichinosis among German prisoners of war.

    Journal of the Royal Army Medical Corps·2010
    Same author

    Early death from clinical stage I melanoma.

    The Journal of investigative dermatology·2010
    Same author

    Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients.

    The Journal of investigative dermatology·2010

    Elective lymph node dissection (ELND) does not improve survival for most clinical stage I melanoma patients. However, a select group with epithelioid in small nests (ESN) melanomas may benefit from this procedure.

    Area of Science:

    • Oncology
    • Dermatology
    • Surgical Oncology

    Background:

    • Clinical stage I melanoma survival rates are consistent across prospective studies, regardless of elective lymph node dissection (ELND).
    • Retrospective studies suggesting survival benefits from ELND are limited by selection bias.

    Purpose of the Study:

    • To evaluate the survival impact of elective lymph node dissection (ELND) in clinical stage I melanoma.
    • To identify specific melanoma subtypes that may benefit from ELND.

    Main Methods:

    • Analysis of prospective studies (randomized and non-randomized) on clinical stage I melanoma.
    • Review of retrospective data to assess potential survival benefits of ELND.
    • Identification of melanoma characteristics associated with lymph node metastasis patterns.

    Related Experiment Videos

    Main Results:

    • Prospective studies show no survival difference with or without ELND for clinical stage I melanoma.
    • Retrospective data suggest a potential survival benefit for a select group of patients.
    • Epithelioid in small nests (ESN) melanomas are identified as a subgroup that may benefit from ELND due to early regional lymph node metastasis without distant spread.

    Conclusions:

    • ELND does not offer a survival advantage for the general population of clinical stage I melanoma patients.
    • Epithelioid in small nests (ESN) melanomas represent a specific subtype where ELND might be life-saving.
    • Dermatologists should encourage participation in randomized trials to further refine patient selection for ELND.